These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 23478537)

  • 1. Prostate cancer: why is PSA velocity such a sticky concept?
    Vickers AJ
    Nat Rev Urol; 2013 Apr; 10(4):189-90. PubMed ID: 23478537
    [No Abstract]   [Full Text] [Related]  

  • 2. If something looks too good to be true, it probably is.
    Vickers AJ
    BJU Int; 2013 Aug; 112(4):430-1. PubMed ID: 23879905
    [No Abstract]   [Full Text] [Related]  

  • 3. Changes in serum prostate-specific antigen levels and the identification of prostate cancer in a large managed care population.
    Wallner LP; Frencher SK; Hsu JW; Chao CR; Nichol MB; Loo RK; Jacobsen SJ
    BJU Int; 2013 Jun; 111(8):1245-52. PubMed ID: 23320750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The interplay between obesity and the accuracy of prostate-specific antigen (PSA) for predicting prostate cancer.
    Granieri MA; Freedland SJ
    BJU Int; 2013 Aug; 112(4):E272. PubMed ID: 23879911
    [No Abstract]   [Full Text] [Related]  

  • 5. Words of wisdom. Re: PSA density improves prediction of prostate cancer.
    Roobol MJ
    Eur Urol; 2014 Nov; 66(5):964-5. PubMed ID: 25763443
    [No Abstract]   [Full Text] [Related]  

  • 6. Significance of examination of prostate-specific antigen and prostate-specific antigen density in patients with prostatic hyperplasia and prostate cancer.
    Romics I; Frang D; Bodrogi I
    Int Urol Nephrol; 1997; 29(4):449-55. PubMed ID: 9406003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive analysis of post-diagnostic prostate-specific antigen kinetics as predictor of a prostate cancer progression in active surveillance patients.
    Iremashvili V; Manoharan M; Lokeshwar SD; Rosenberg DL; Pan D; Soloway MS
    BJU Int; 2013 Mar; 111(3):396-403. PubMed ID: 22703025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What are the consequences if i postpone treatment of my PSA-detected prostate cancer?
    Sampson JN
    Cancer Epidemiol Biomarkers Prev; 2011 May; 20(5):727-8. PubMed ID: 21546364
    [No Abstract]   [Full Text] [Related]  

  • 9. [Significance of the PSA-concentration for the detection of prostate cancer].
    Stachon A
    Pathologe; 2005 Nov; 26(6):469-72. PubMed ID: 16195861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Editorial comment on: decision-making about PSA testing and prostate biopsies: a qualitative study embedded in a primary care randomised trial.
    Finney Rutten LJ
    Eur Urol; 2008 Jun; 53(6):1193. PubMed ID: 17709172
    [No Abstract]   [Full Text] [Related]  

  • 11. Dissecting the dynamics of serum prostate-specific antigen.
    Vollmer RT
    Am J Clin Pathol; 2010 Feb; 133(2):187-93. PubMed ID: 20093227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate cancer with low PSA levels.
    Glaser AI
    N Engl J Med; 2004 Oct; 351(17):1802-3. PubMed ID: 15499670
    [No Abstract]   [Full Text] [Related]  

  • 13. Re: The Impact of Obesity on the Predictive Accuracy of PSA in Men Undergoing Prostate Biopsy.
    Kaplan SA
    J Urol; 2015 Aug; 194(2):394-5. PubMed ID: 26195366
    [No Abstract]   [Full Text] [Related]  

  • 14. PSA density and early prostate cancer detection.
    Christensen JG
    Urology; 1994 Jul; 44(1):150-1. PubMed ID: 7518978
    [No Abstract]   [Full Text] [Related]  

  • 15. [Importance of PSA velocity and PSA density in the prediction of prostate cancer in TURP or open prostatectomy specimen of patients with previous negative prostate biopsy].
    Rodríguez Alonso A; González Blanco A; Barbagelata López A; Pita Fernández S; Suárez Pascual G; Bonelli Martín C; Cuerpo Pérez M
    Actas Urol Esp; 2008 Sep; 32(8):779-86. PubMed ID: 19013975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia.
    Haese A; Graefen M; Noldus J; Hammerer P; Huland E; Huland H
    J Urol; 1997 Dec; 158(6):2188-92. PubMed ID: 9366341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving Prostate Cancer Screening and Diagnosis: Health Policy and Biomarkers Beyond PSA.
    Patel HD; Chalfin HJ; Carter HB
    JAMA Oncol; 2016 Jul; 2(7):867-8. PubMed ID: 27031887
    [No Abstract]   [Full Text] [Related]  

  • 18. [Additional aids in detection of prostate carcinomas? PSA-prostatic volume quotient, PSA-doubling time, age-dependent PSA reference values and PSA in urine].
    Pannek J; Brands FH
    Urologe A; 2000 Jul; 39(4):324-9. PubMed ID: 10957773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of prostate specific antigen and prostate specific antigen density in the diagnosis of prostate cancer in a community based urology practice.
    Rommel FM; Agusta VE; Breslin JA; Huffnagle HW; Pohl CE; Sieber PR; Stahl CA
    J Urol; 1994 Jan; 151(1):88-93. PubMed ID: 7504748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of PSA and percent free PSA for staging and prognosis prediction in clinically localized prostate cancer.
    Pannek J; Partin AW
    Semin Urol Oncol; 1998 Aug; 16(3):100-5. PubMed ID: 9741413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.